ARA-290 belongs to the class of erythropoietin derivatives known as EPO-mimetic peptide (EMP) agents. Unlike EPO, Ara-290 has been designed to selectively target the tissue-protective receptor (TPR) without eliciting erythropoiesis, thereby providing cytoprotection without the risk of undesirable hematopoietic side effects. Ara-290 has shown promising results in the treatment of neuropathic pain, particularly in patients with sarcoidosis.
Furthermore, Ara-290 has demonstrated beneficial effects in the treatment of diabetic neuropathy and myocardial infarction. It reduced neuronal loss, improved nerve function, and enhanced myocardial repair and functional recovery in animal models.
Showing all 3 results
[1] https://pubmed.ncbi.nlm.nih.gov/25387363/
[2] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC3563705/
[3] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC3883966/
[4] https://www.tandfonline.com/doi/ full/10.1517/21678707.2013.719289
[5] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC8917853/
[6] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC4365069/
[7] https://www.sciencedirect.com/science/ article/pii/S074152141301238X
[8] https://www.researchgate.net/ publication/310146980
[9] https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC5741312/
ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.
DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Direct Peptides website: https://united-kingdom.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.
401 N. Mills Ave, Ste B, Orlando, FL 32803, United States